02/22/2013 Press Release
Viant Advises Arcam on its Strategic Alliance with DiSanto Technology

February 22, 2013. Viant Capital LLC (“Viant”) is pleased to announce it acted as the exclusive financial advisor to Arcam AB (“Arcam”) listed on NASDAQ OMX Stockholm, Sweden (Ticker: ARCM) and market leader in EBM-based Additive Manufacturing technology on its strategic alliance with DiSanto Technology Inc. (“DTI”), a full-service medical device services contract manufacturer based in Shelton, CT, USA.

The strategic alliance combines Arcam’s leading Additive Manufacturing EBM technology with DTI’s full-service product application development and contract manufacturing. As part of the strategic alliance agreement, Arcam will provide capital to and arrange financing for DTI to support its EBM-based manufacturing capability, including DTI’s initial purchase of two EBM systems. The securities underlying the financing provide for potential minority cross-ownership positions in each other. Furthermore, as part of the strategic alliance, Arcam has an option to acquire DTI in its entirety any time during the first two years of the strategic alliance. The strategic alliance agreement is conditional upon the approval by Arcam’s shareholders at an Arcam General Meeting.

“This partnership with DTI is an important strategic step for Arcam. Our EBM technology has been used for manufacturing of implants in Europe since 2007, and in the US since 2010. To date some 30,000 orthopedic implants manufactured with EBM technology have been implanted worldwide. Arcam has many customers that have purchased EBM systems to develop and manufacture EBM-based product applications. Through this alliance with DTI, we will now also be able to offer existing and new customers contract manufacturing capabilities and help them commercialize new product applications. This will in turn give our customers the opportunity to more quickly and more efficiently develop products and get them to the market”, says Magnus René, CEO of Arcam.

David Reilly, Managing Director of Viant, added “This strategic alliance has such compelling strategic rationale. We at Viant are proud to have initiated and advised on this transaction on behalf of Arcam. It represents an opportunity to potentially accelerate market adoption and penetration of commercially manufactured EBM-based implants and to potentially transform Arcam’s business by providing a platform, through its option to acquire DTI, to enter the large implant manufacturing market with Arcam’s proprietary EMB technology.”

About Arcam AB

Arcam provides a cost-efficient Additive Manufacturing solution for production of metal components. The technology offers freedom in design combined with excellent material properties and high productivity. Arcam’s market is global with customers mainly in the orthopedic and aerospace industries. The company was founded in 1997 and is listed on NASDAQ OMX Stockholm, Sweden. Head office and production facilities are located in Mölndal, Sweden. Support offices are located in the US, UK, Italy and China (

About Viant Capital LLC

Advising on mergers, acquisitions, divestitures, sales, and private placement financings, Viant Capital is an investment banking firm that provides financial advisory and other investment banking services (

For further information, go to the Arcam AB press release.

« back to news page
News Archive